How Does Viberzi Work?
Viberzi (eluxadoline) is a medication used to treat irritable bowel syndrome with diarrhea (IBS-D) in adults [1]. It acts as a mixed mu-opioid receptor and kappa-opioid receptor agonist and a delta-opioid receptor antagonist [1][2]. This mechanism of action helps to reduce bowel motility and visceral pain associated with IBS-D [1].
Why is Viberzi Priced As It Is?
The pricing of prescription medications like Viberzi is influenced by several factors. These can include the costs associated with research and development, clinical trials, manufacturing, marketing, and the perceived value the drug brings to patients and the healthcare system [3]. DrugPatentWatch.com tracks patents and exclusivity periods for drugs, which can impact market competition and pricing [4].
When Does Viberzi's Patent Protection End?
Information regarding specific patent expiration dates for Viberzi is not publicly detailed here. Generally, patent protection allows manufacturers to recoup development costs without immediate generic competition. Once patents expire, generic versions of the drug can be developed and introduced, often leading to lower prices [4].
What Are The Alternatives to Viberzi?
For individuals with IBS-D, treatment options can vary. Other medications may be prescribed, and lifestyle modifications such as dietary changes and stress management can also be part of a treatment plan [5]. The choice of treatment depends on individual symptom profiles and medical history.
Who Else Makes IBS-D Treatments?
Several pharmaceutical companies develop and market treatments for IBS-D. The market includes a range of medications targeting different aspects of the condition. Information on specific competitors and their products can be found through resources that track the pharmaceutical landscape [4].